
´Ù½øNKϸ°ûÀ©ÔöºÍ»î»¯£ºIL-2/21
Soiffer RJµÈ×Ô1996ÄêÆð¼´±¨µÀIL-2µÍ¼ÁÁ¿³ÖÐøÊä×¢ºÍ¼äЪ¸øÒ©¶Ô×ªÒÆ°©»¼ÕßµÄCD56+NKϸ°ûÓÐÃ÷ÏÔÀ©ÔöЧ¹û¡£´ó²¿·ÖNKϸ°û±íÃæ¾ßÓÐIL-2ÖÐÇ׺ÍÐÔÊÜÌ壬IL-2ÓÕµ¼NKµÄɱÉË»îÐÔÔ¼Ðè18¡«24Сʱ¡£´ËÍ⣬IL-2»¹¿ÉÓÕµ¼NKϸ°ûµÄÔöÖ³£¬Ò»°ãÔڴ̼¤ºó3¡«4Ì쿪ʼ·¢ÉúÔöÖ³£¬Æä»úÀíΪIL-2¿ÉÓÕµ¼NKϸ°û±í´ïIL-2R¦ÁÁ´£¬Ð±í´ïµÄ¦ÁÁ´ÓëÔÏÈϸ°û±íÃæµÄ¦ÂÁ´ºÍ¦ÃÁ´½áºÏÐγɸßÇ׺ÍÐÔÊÜÌ壬ÔÚIL-2´æÔÚÏ´̼¤NKϸ°û·¢ÉúÔöÖ³¡£

ͼƬÀ´Ô´£ºSharma R, et al. Immunol Res. 2018
Wendt KµÈ±¨µÀ£¬ÔÚ¶ÔNKϸ°û¹¦Äܵĵ÷¿ØÖУ¬µ¥¶ÀʹÓÃIL-2ÄÜ´Ù½øÈËNKϸ°ûµÄÔöÖ³£¬IL-2ºÍIL-21ÁªºÏÔò²úÉú¸üÃ÷ÏÔµÄÔöֳЧ¹û¡£

ͼƬÀ´Ô´£ºWendt K, et al. Immunology. 2007
Li QµÈ±¨µÀIL-21¶ÔÀëÌåÅàÑøµÄÈËÔ´NKϸ°û²úÉúÃ÷ÏÔµÄÀ©ÔöЧ¹û£¬Ï¸°ûÊýÁ¿³ÊŨ¶ÈÒÀÀµÐÔÔö¼Ó£¬ÔÚÅàÑøµÄµÚ1~2ÖÜÄÚÒ²´Ù½øÀ©Ôöϸ°û½øÈëϸ°ûÖÜÆÚSÆÚ¡£

ͼƬÀ´Ô´£ºLi Q, et al. Immunobiology. 2015.
ÓÕµ¼·Ö»¯NKϸ°û£ºIL-1¦Â/12/15
NKϸ°ûµÄÃâÒß±íÐÍΪCD3-CD56+£¬Ä¿Ç°´ó¶àÈÏΪÆäÓɹÇËèÔìѪ¸Éϸ°ûÖ±½Ó·Ö»¯£¬¼´ÓÉCD34+ÔìѪ¸Éϸ°û·Ö»¯¶øÀ´¡£´óÁ¿ÊµÑé֤ʵ£¬¹ÇËèÀ´Ô´µÄCD34+ϸ°û¿ÉÒÔÔÚÌåÍâ¾Ï¸°ûÒò×ÓÓÕµ¼·Ö»¯ÎªNKϸ°û£¬ÕâΪNKϸ°ûµÄÀ´Ô´ÌṩÁËÁíÍâÒ»ÖÖÑ¡Ôñ¡£
Ambrosini PµÈ·ÖÎöIL-1¦Â¶ÔÆê´øÑªCD34+ǰÌåϸ°ûNKϸ°û·Ö»¯µÄÓ°Ï죬Êý¾Ý±íÃ÷IL-1¦ÂÒÖÖÆILC3£¬Í¬Ê±´Ù½øÆê´øÑªCD34+ǰÌåNKϸ°ûµÄ³ÉÊì¡£

ͼƬÀ´Ô´£ºAmbrosini P et al. Eur J Immunol. 2015. PMID: 25847448
Àîì͵ȶԼ±ÐÔËèϵ°×Ѫ²¡»¼Õß¹ÇËèÀ´Ô´CD34+°×Ѫ²¡Ï¸°û½øÐÐÌåÍâÓÕµ¼·Ö»¯ÊµÑ飬CD34+°×Ѫ²¡Ï¸°û¿ÉÔÚÌåÍâÓÕµ¼·Ö»¯ÎªNKϸ°û£¬ÇÒ¾ßÓÐɱÉË»îÐÔ¡£ÁªºÏÓ¦ÓÃIL-12¡¢1L-15ϸ°ûÒò×Ó×éºÏÄܹ»ÓÕµ¼·Ö»¯µÄNKϸ°û»îÐÔ£¬Ìá¸ß¶Ô°×Ѫ²¡Ï¸°ûµÄɱÉËÂÊÒÔ¼°TNF-¦ÁºÍIFN-¦ÃµÈ»ùÒò±í´ïˮƽ¡£

ͼƬÀ´Ô´£ºÀîìÍ µÈ.ÁÙ´²Ö×ÁöѧÔÓÖ¾,2019.
ÔöÇ¿NKϸ°û¶¾ÐÔ×÷ÓãºIL-12/18/21

ͼƬÀ´Ô´£ºGuia S, et al. Blood. 2008
Mirja?i? µÈ̽¾¿IL-12ºÍIL-18¶Ô×ªÒÆÐÔºÚÉ«ËØÁö»¼ÕßNKϸ°û¼°ÆäÑÇȺ¹¦ÄܺÍÊÜÌåÌØÕ÷µÄÓ°Ï죬IL-12ºÍIL-18ÌåÍâÁªºÏÖÎÁƶÔ×ªÒÆÐÔºÚÉ«ËØÁö»¼ÕßNKϸ°û¶¾ÐÔºÍCD25ÊÜÌå±í´ï¿É²úÉúÁ¼ºÃЧ¹û¡£

ͼƬÀ´Ô´£ºMirja?i? et al.. J Transl Med. 2015. PMID: 25889680.
Strengell MµÈÒ²Ôø±¨µÀIL-21ÓëIL-15»òIL-18Ðͬ×÷ÓÿÉÔöÇ¿ÈËNKϸ°ûºÍTϸ°ûÖÐIFN- ¦ÃµÄ²úÉú£¬·¢»Óϸ°û¶¾×÷Óá£

ͼƬÀ´Ô´£ºStrengell M, et al. J Immunol. 2003.
±±¾©¾º¼¼±¦¹ÙÍøÉúÎï³ÉÁ¢Ê®ÓàÄêһֱרעCGTÁìÓòGMP¼¶ºËÐÄÊÔ¼ÁÔÁÏÑз¢Éú²ú£¬²¢ÎªÉúÃü¿ÆÑ§ÌṩÍêÉÆµÄÕûÌå½â¾ö·þÎñ·½°¸¡£¹«Ë¾ÓµÓÐÕæºËÓëԺ˵°°×±í´ï¹¤³Ìƽ̨¡¢Ï¸°ûÅàÑø¼¼Êõ¿ª·¢Æ½Ì¨ºÍÌåÍâÕï¶ÏÊÔ¼ÁÉú²úƽ̨£¬Éú²úµÄGMP¼¶ÖØ×éµ°°×¾ßÓеÍÄÚ¶¾ËØ¡¢¸ß´¿¶È¡¢¸ß»îÐÔ¡¢¸ßÅú¼äÒ»ÖÂÐÔµÈÌØµã£¬Í¬Ê±ÌṩµÄ´¿Òò×Ó·¨Ï¸°ûÅàÑøÊÔ¼ÁºÐÌ××°»î»¯À©ÔöЧÂʸߣ¬ÐÔÄÜÁìÏÈ¡£Ä¿Ç°¹«Ë¾ÖØ×éµ°°×ºÍϸ°ûÅàÑøÊÔ¼ÁÌ××°²úÏߵȹؼüÔÁϲúÆ·¾ùÒÑÍê³ÉFDA DMF±¸°¸£¬¿ÉÂú×ã¿Í»§Ï¸°ûÒ©ÎïÉ걨ÐèÇó¡£


Fig1£ºRecombinant Human IL-1¦Â stimulates secretion of IFN-¦Ã by NK-92 human natural killer lymphoma cells

Fig2£ºRecombinant Human IL-12 stimulates proliferation of PBMC

Fig3£ºRecombinant Human IL-15 stimulates proliferation of CTLL-2

Fig4£ºRecombinant Human IL-18 stimulates proliferation of KG-1
?ÖØ×éÈËIL-21µ°°×

Fig5£ºRecombinant human IL-21 protein stimulates secretion of IFN- ¦Ã by NK-92
?NK×Üϸ°ûÀ©Ôö±ä»¯

?NKϸ°û»îÂʱ仯

?NKϸ°ûÀ©Ôö±ÈÀý

²Î¿¼ÎÄÏ×£º
Soiffer RJ, Murray C, Shapiro C, Collins H, Chartier S, Lazo S, Ritz J. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. Clin Cancer Res. 1996 Mar;2(3):493-9. PMID: 9816195
Sharma R, Das A. IL-2 mediates NK cell proliferation but not hyperactivity. Immunol Res. 2018 Feb;66(1):151-157. PMID: 29256180.
Wendt K, Wilk E, Buyny S, Schmidt RE, Jacobs R. Interleukin-21 differentially affects human natural killer cell subsets. Immunology. 2007 Dec;122(4):486-95. PMID: 17635612
Li Q, Ye LJ, Ren HL, Huyan T, Li J, Shi JL, Huang QS. Multiple effects of IL-21 on human NK cells in ex vivo expansion. Immunobiology. 2015 Jul;220(7):876-88. doi: 10.1016/j.imbio.2015.01.009. Epub 2015 Jan 31. PMID: 25758713.
Àîçù,÷Æä±ú,ÕÅÃ÷½ÜµÈ.°×ϸ°û½éËØ¶ÔNKϸ°ûµÄµ÷¿Ø×÷Óü°Æä·Ö×Ó»úÖÆ[J].ÃâÒßѧÔÓÖ¾,2012,28(12):1081-1085+1089.
Ambrosini P, Loiacono F, Conte R, Moretta L, Vitale C, Mingari MC.
IL-1¦Â inhibits ILC3 while favoring NK-cell maturation of umbilical cord blood CD34(+) precursors. Eur J Immunol. 2015 Jul;45(7):2061-71. Erratum in: Eur J Immunol. 2015 Aug;45(8):2420. PMID: 25847448
ÀîìÍ,Ò¶¾´Î°,¹ùÏþÁá.IL-12¡¢IL-15¶Ô¼±ÐÔËèϵ°×Ѫ²¡»¼Õß¹ÇËèÀ´Ô´CD34+°×Ѫ²¡Ï¸°ûת»¯ÎªNKϸ°û×÷ÓÃÑо¿[J].ÁÙ´²Ö×ÁöѧÔÓÖ¾,2019,24(01):32-37.
Guia S, Cognet C, de Beaucoudrey L, Tessmer MS, Jouanguy E, Berger C, Filipe-Santos O, Feinberg J, Camcioglu Y, Levy J, Al Jumaah S, Al-Hajjar S, Stephan JL, Fieschi C, Abel L, Brossay L, Casanova JL, Vivier E. A role for interleukin-12/23 in the maturation of human natural killer and CD56+ T cells in vivo. Blood. 2008 May 15;111(10):5008-16. PMID: 18319400.
Mirja?i? Martinovi? K, Babovi? N, D?odi? R, Juri?i? V, Matkovi? S, Konjevi? G. Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients. J Transl Med. 2015 Apr 14;13:120. PMID: 25889680.
Strengell M, Matikainen S, Sir¨¦n J, Lehtonen A, Foster D, Julkunen I, Sareneva T. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol. 2003 Jun 1;170(11):5464-9. PMID: 12759422.
Waldmann TA. Cytokines in Cancer Immunotherapy. Cold Spring Harb Perspect Biol. 2018 Dec 3;10(12):a028472. PMID: 29101107.
ÖÜÒ» ÖÁ ÖÜÎå
09:00-17:30
רҵɨÂë»ñÈ¡
רҵ×Éѯ·þÎñ
